A detailed history of Driehaus Capital Management LLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Driehaus Capital Management LLC holds 2,091,801 shares of TERN stock, worth $11.7 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
2,091,801
Previous 1,083,905 92.99%
Holding current value
$11.7 Million
Previous $7.38 Million 136.35%
% of portfolio
0.17%
Previous 0.08%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.49 - $10.8 $6.54 Million - $10.9 Million
1,007,896 Added 92.99%
2,091,801 $17.4 Million
Q1 2024

May 15, 2024

SELL
$4.86 - $8.19 $224,274 - $377,943
-46,147 Reduced 4.08%
1,083,905 $7.11 Million
Q4 2023

Feb 14, 2024

SELL
$3.37 - $6.86 $1.64 Million - $3.35 Million
-487,868 Reduced 30.15%
1,130,052 $7.33 Million
Q3 2023

Nov 14, 2023

SELL
$4.7 - $8.55 $18,137 - $32,994
-3,859 Reduced 0.24%
1,617,920 $8.14 Million
Q2 2023

Aug 14, 2023

SELL
$7.35 - $13.29 $6.23 Million - $11.3 Million
-847,733 Reduced 34.33%
1,621,779 $14.2 Million
Q1 2023

May 15, 2023

BUY
$7.91 - $12.0 $1.39 Million - $2.1 Million
175,136 Added 7.63%
2,469,512 $29.2 Million
Q4 2022

Feb 14, 2023

BUY
$4.62 - $10.18 $3.22 Million - $7.09 Million
696,447 Added 43.58%
2,294,376 $23.4 Million
Q3 2022

Nov 14, 2022

BUY
$1.87 - $6.42 $2.6 Million - $8.91 Million
1,387,855 Added 660.65%
1,597,929 $9.41 Million
Q2 2022

Aug 15, 2022

BUY
$1.5 - $3.0 $262,461 - $524,922
174,974 Added 498.5%
210,074 $521,000
Q1 2022

May 16, 2022

BUY
$2.83 - $6.7 $99,333 - $235,170
35,100 New
35,100 $104,000

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $211M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.